Company intelligence / Profile preview

CDBIO

Seoul, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

CDBIO is a biotechnology and digital healthcare company that leverages proprietary Quantum Bio Technology to develop innovative diagnostic and therapeutic solutions. The company's core platform utilizes quantum mechanics to analyze biological frequencies, enabling non-invasive health monitoring and the discovery of what it terms "Quantum Drugs." CDBIO is primarily focused on addressing chronic and complex conditions such as diabetes, cancer, and neurodegenerative diseases. By integrating digital bio-sensors with therapeutic development, the company aims to provide a comprehensive ecosystem for personalized medicine and real-time disease management.

Therapeutic areas: OncologyEndocrinologyNeurology
Modalities: Small moleculeDigital TherapeuticsQuantum Bio Drugs
Industry: Biotech

Partnerships

Quantum Bio Research InstituteKorea University

Beyond the preview

Go deeper on CDBIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDBIO.

Explore the full profile